| Gan & Lee Pharmaceuticals7 programs in shared conditions | 4 · 3 with both in phase 3Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity +1 | GZR4, GZR33, bofanglutide | - Gan & Lee Pharmaceuticals’ bofanglutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 2, NCT06778967)
- Gan & Lee Pharmaceuticals’ bofanglutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 2, NCT06256549)
- Gan & Lee Pharmaceuticals’ bofanglutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Obesity, NCT07150975)
- and 2 more
|
| Eli Lilly and Company21 programs in shared conditions | 8 · 5 with both in phase 3Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 +5 | retatrutide, baricitinib, Tirzepatide +3 | - Eli Lilly and Company’s retatrutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, NCT06982859)
- Eli Lilly and Company’s retatrutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 2, NCT06260722)
- Eli Lilly and Company’s LY4057996 in a combination vs insulin degludec (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 1, NCT06945406)
- and 2 more
|
| Jiangsu HengRui Medicine Co., Ltd.19 programs in shared conditions | 8 · 3 with both in phase 3Diabetes Mellitus, Type 2, Hypertension, Obesity +5 | SHR-3167, ribupatide, HRS-1780 +1 | - Jiangsu HengRui Medicine Co., Ltd.’s ribupatide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Obesity, NCT07285902)
- Jiangsu HengRui Medicine Co., Ltd.’s SHR-3167 in a combination vs insulin degludec (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 2, NCT07913061)
- Jiangsu HengRui Medicine Co., Ltd.’s SHR-3167 in a combination vs insulin degludec (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 2, NCT07018453)
|
| Boehringer Ingelheim4 programs in shared conditions | 4 · 2 with both in phase 3Diabetes Mellitus, Type 2, Obesity, Heart Failure +1 | survodutide, vicadrostat, empagliflozin | - Boehringer Ingelheim’s survodutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Obesity, NCT06745284)
- Boehringer Ingelheim’s survodutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Obesity, NCT05202353)
|
| Carnot Laboratories1 program in shared conditions | 2 · 2 with both in phase 3Diabetes Mellitus, Type 2, Obesity | bofanglutide | - Carnot Laboratories’ bofanglutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 2, NCT07628985)
- Carnot Laboratories’ bofanglutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Obesity, NCT07622810)
|